Welcome to our dedicated page for Structure Therapeutics American Depositary Shares news (Ticker: GPCR), a resource for investors and traders seeking the latest updates and insights on Structure Therapeutics American Depositary Shares stock.
Structure Therapeutics Inc. (NASDAQ: GPCR) is a clinical-stage biopharmaceutical company revolutionizing the treatment of chronic diseases through innovative oral therapeutics. The company’s lead product candidate, GSBR-1290, is an oral small molecule agonist targeting the glucagon-like-peptide-1 receptor (GLP-1R), a proven drug target for type-2 diabetes and obesity. By focusing on GPCRs, Structure Therapeutics aims to address significant unmet medical needs in metabolic and cardiopulmonary diseases.
In recent developments, Structure Therapeutics reported promising results from its Phase 1b study of GSBR-1290, showcasing its potential as a differentiated oral GLP-1 receptor agonist. The company is advancing GSBR-1290 into Phase 2 trials, aiming to further demonstrate its efficacy and safety in treating type-2 diabetes and obesity. Additionally, the company is developing other oral small-molecule therapeutics, including ANPA-0073 and LTSE-2578, targeting pulmonary and cardiovascular diseases.
Financially, Structure Therapeutics is in a robust position, with a cash reserve of $205.4 million as of September 30, 2023, and an additional $300 million raised through private placement in October 2023. This strong financial backing will support the advancement of the company’s clinical programs and achieve key milestones through 2026.
Structure Therapeutics' commitment to scientific innovation is evident in its next-generation structure-based drug discovery platform, which underpins its GPCR-targeted pipeline. The company’s strategic partnerships with leading healthcare investors further bolster its mission to deliver transformative oral therapies to patients worldwide.
For more information, visit www.structuretx.com.
Structure Therapeutics (NASDAQ: GPCR) has announced ACCG-2671 as its lead oral small molecule amylin receptor agonist for obesity treatment. The drug, designed as an oral Dual Amylin and Calcitonin Receptor Agonist (DACRA), is expected to enter Phase 1 clinical trials by year-end 2025.
Preclinical studies showed ACCG-2671 demonstrates potent target engagement, robust weight loss, and favorable safety profile supporting once-daily dosing. The company positions it as the most advanced oral small molecule amylin-based drug candidate, complementing their GLP-1 oral molecule GSBR-1290, with both intended for use as monotherapies and in fixed-dose combinations.
The drug showed cagrilintide-like efficacy in preclinical data with an oral small molecule profile, targeting amylin, a hormone that regulates glycemia and energy balance.
Structure Therapeutics (NASDAQ: GPCR), a clinical-stage biopharmaceutical company focused on developing oral small molecule therapeutics for metabolic and cardiopulmonary diseases, has announced its participation in the Jefferies London Healthcare Conference. The event will take place from November 19-21, 2024, in London, UK.
The company's management will deliver a presentation and participate in a fireside chat on Wednesday, November 20 at 8:00 a.m. GMT, while also hosting one-on-one meetings. A live webcast will be available on the company's website, with a replay accessible for 90 days following the event.
Structure Therapeutics (NASDAQ: GPCR) reported Q3 2024 financial results and recent milestones. The company has initiated Phase 2b ACCESS study of GSBR-1290 for obesity treatment, with topline data expected in Q4 2025. The company maintains a strong financial position with $915.3 million in cash and investments, expected to fund operations through 2027. Q3 2024 financial results show R&D expenses of $32.6 million (up from $17.5M in Q3 2023), G&A expenses of $13.2 million (up from $8.6M), and a net loss of $34.0 million. The company plans to select an oral small molecule amylin receptor agonist development candidate by end of 2024.
Structure Therapeutics has initiated dosing in its Phase 2b ACCESS clinical study for GSBR-1290, an oral small molecule GLP-1 receptor agonist for obesity treatment. The study will evaluate multiple doses up to 120 mg over 36 weeks in approximately 220 participants. Additionally, the company announced the Phase 2 ACCESS II study, which will test higher doses (180 and 240 mg) in about 82 participants. Both studies employ a "low and slow" titration approach, with topline data expected in Q4 2025. GSBR-1290 has shown competitive weight loss results and favorable safety in previous studies with once-daily dosing.
Structure Therapeutics (NASDAQ: GPCR) has announced multiple poster presentations at ObesityWeek® 2024, scheduled for November 3-6, 2024 in San Antonio, TX. The company will present three posters focusing on obesity treatment innovations:
1. A presentation on novel oral small molecule dual amylin and calcitonin receptor agonists for obesity treatment
2. Research on drug design principles and PK/PD of GSBR-1290, a small molecule GLP-1RA
3. Clinical results showing significant weight changes at 12 weeks with GSBR-1290
All presentations will take place in Exhibit Hall 4, with specific sessions scheduled for November 3-4.
Structure Therapeutics Inc. (NASDAQ: GPCR) has announced key leadership changes to drive its next phase of development. Blai Coll, M.D., Ph.D., has been promoted to Chief Medical Officer, replacing Mark Bach, M.D., Ph.D., effective September 18, 2024. Dr. Coll has been leading the GSBR-1290 program, an oral small molecule GLP-1 agonist for obesity, set to enter Phase 2b clinical trials in Q4 2024.
Additionally, Ashley Hall, J.D., has been appointed as Chief Development Officer, a new position overseeing clinical development operations, project management, regulatory affairs, and quality assurance. These appointments aim to strengthen the company's position as it advances its clinical programs, including the development of an oral amylin compound.
Structure Therapeutics Inc. (NASDAQ: GPCR) has appointed Angus C. Russell to its board of directors. Mr. Russell, former CEO of Shire plc, brings over 30 years of experience in the global biopharmaceutical industry. This appointment comes as Structure prepares to advance its oral small molecule GLP-1 agonist, GSBR-1290, into late-stage clinical development for obesity. CEO Raymond Stevens highlighted Russell's expertise in strategy, finance, operations, and commercialization as valuable assets for the company's growth. Russell expressed enthusiasm for Structure's potential in the obesity market, particularly with GSBR-1290 and its pipeline of oral small molecule therapeutics.
Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company focusing on novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, has announced its participation in two upcoming investor conferences in September 2024:
1. Morgan Stanley 22nd Annual Global Healthcare Conference: Fireside chat on Thursday, September 5 at 10:00 a.m. EDT
2. Cantor Fitzgerald Global Healthcare Conference 2024: Fireside chat on Thursday, September 19 at 9:10 a.m. EDT
Live and archived webcasts of both fireside chats will be available on the company's website, with replays accessible for 90 days after the events.
Structure Therapeutics (NASDAQ: GPCR) reported Q2 2024 financial results and recent highlights. Key points include:
1. GSBR-1290 Phase 2b obesity study on track for Q4 2024 initiation.
2. Oral small molecule amylin receptor agonist development candidate expected in Q4 2024.
3. Strong financial position with $927.1 million cash balance, funding operations through at least 2027.
4. Q2 2024 R&D expenses increased to $22.1 million from $19.4 million in Q2 2023.
5. Q2 2024 G&A expenses rose to $11.3 million from $6.6 million in Q2 2023.
6. Net loss for Q2 2024 was $26.0 million, compared to $23.3 million in Q2 2023.
7. GSBR-1290 Phase 2a results showed 6.2% placebo-adjusted mean weight loss at 12 weeks.
Structure Therapeutics (NASDAQ: GPCR) announced the closing of its upsized public offering of 10,427,017 American depositary shares (ADSs), each representing three ordinary shares, at $52.50 per ADS. The offering, which included the full exercise of the underwriters' option to purchase an additional 1,360,045 ADSs, generated gross proceeds of around $547.4 million. The proceeds are subject to underwriting discounts, commissions, and offering expenses. The offering was managed by Goldman Sachs, Morgan Stanley, Jefferies, Leerink Partners, Guggenheim Securities, and BMO Capital Markets. The registration statements for the securities became effective on June 5, 2024.
FAQ
What is the current stock price of Structure Therapeutics American Depositary Shares (GPCR)?
What is the market cap of Structure Therapeutics American Depositary Shares (GPCR)?
What is Structure Therapeutics Inc.'s main focus?
What is GSBR-1290?
What recent financial achievements has Structure Therapeutics made?
What are the other therapeutic candidates in the pipeline?
How does Structure Therapeutics plan to use the proceeds from the recent financing?
What makes Structure Therapeutics' drug discovery platform unique?
Who are the key partners in the recent private placement financing?
What are the company's plans for GSBR-1290 in 2024?
How is Structure Therapeutics addressing the unmet medical needs?
Where can I find more information about Structure Therapeutics?
